At its peak, the company was estimated to be worth US$11.8 billion (NZ$16.7 billion), with Holmes' 50 per cent stake putting her personal net worth at US$5.9 billion (NZ$8.3 billion), making her America's youngest female billionaire.
The ruse began to unravel following the publication of a bombshell expose by the Journal in October 2015, which revealed the much-hyped technology was in fact a sham, and the vast majority of the company's blood testing was conducted using competitors' products.
What followed were a string of investigations by numerous US authorities, lawsuits from disgruntled investors, the closure of labs, and the sacking of 340 staff as the company attempted to salvage something from the wreckage.
The vastly lowered valuation of the company in the wake of the scandal meant many investors' shares, purchased for $US15 (NZ$21) to $US17 (NZ$24) each, have lost most of their value. High-profile investors included Rupert Murdoch, executive chairman of News Corp - publisher of news.com.au - and US Education Secretary Betsy DeVos.
Warmenhoven told the Journal Holmes' share offer showed "a level of selflessness and grace reflecting her commitment to the company's success".